Overview
- In a Spanish real‑world study of 200 symptomatic patients, adding plasma p‑tau217 raised diagnostic accuracy from 75.5% to 94.5%.
- The blood test prompted diagnosis changes in about one in four cases and increased clinicians’ confidence from 6.90 to 8.49 on a 10‑point scale.
- A Nature Medicine study developed plasma %p‑tau217 clock models that forecast the timing of symptomatic Alzheimer’s with a median absolute error of about 3.0–3.7 years.
- Age at biomarker positivity influenced timelines, with a median 20.5 years symptom‑free at age 60 versus 11.4 years at age 80.
- Models were trained and validated in Knight ADRC and ADNI cohorts and showed cross‑platform feasibility with assay‑dependent performance, and the authors cautioned they are not yet suitable for routine clinical decisions.